Vivos Therapeutics Issues $12 Million Preferred for SOD Stake and Test IP

Vivos Therapeutics completed a stock-and-asset transaction, issuing $12 million of Series C Convertible Preferred for approximately 11% of SOD Sciences and a 50% co-ownership interest in a pseudohypoxia early-warning test and related intellectual property.